Compare EVO & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | BRSP |
|---|---|---|
| Founded | 1993 | 2017 |
| Country | Germany | United States |
| Employees | 4553 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 934.1M | 764.7M |
| IPO Year | N/A | 2017 |
| Metric | EVO | BRSP |
|---|---|---|
| Price | $2.73 | $5.76 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $7.00 | $6.50 |
| AVG Volume (30 Days) | 95.9K | ★ 786.6K |
| Earning Date | 04-08-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 11.03% |
| EPS Growth | N/A | ★ 75.24 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $330,587,000.00 |
| Revenue This Year | $1.37 | N/A |
| Revenue Next Year | $10.05 | $17.54 |
| P/E Ratio | ★ N/A | $190.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $4.84 |
| 52 Week High | $4.80 | $6.17 |
| Indicator | EVO | BRSP |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 46.09 |
| Support Level | $2.32 | $5.46 |
| Resistance Level | $3.78 | $6.03 |
| Average True Range (ATR) | 0.09 | 0.12 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 19.16 | 37.84 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.